US-China Biotech Relations Face Growing Scrutiny

The U.S.-China biotech relationship is facing increased scrutiny, with concerns about intellectual property theft and state-run companies impacting scientific collaboration. The author, who has covered the biotech and pharma sector for nearly two decades, notes a significant shift in China's role from an emerging market to a key innovator.

China's biotech sector has experienced substantial growth, now accounting for 34% of approximately 14,088 new drugs in global clinical development, surpassing the United States' 27%. Pharmcube data indicates that China contributes 40% of new drugs entering the clinical stage annually. This expansion is further evidenced by a nearly tenfold increase in China's out-licensing deals from 2021 to 2025, reaching a record $137.7 billion.

These developments occur against a backdrop of concerns regarding stolen intellectual property and the influence of China's state-run companies. The author's firsthand experience, including covering the U.S. Food and Drug Administration's first overseas office in China in 2007, underscores the evolving landscape and the potential implications for scientific advancement and U.S. interests.